Effects of Whole-Body Electromyostimulation in Overweight/Obese Postmenopausal Women

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 48 to 60 years
• Women only
• No healthy volunteers
• Adult

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Effects of a 16-Week Whole-Body Electromyostimulation Program on Cardiometabolic Markers, Functional Capacity, and Quality of Life in Overweight/Obese Postmenopausal Women: A Randomized Controlled Trial

Conditions

Postmenopausal Women, Overweight, Obesity

Being tested

Whole-body electromyostimulation (WB-EMS) training, Supervised exercise without whole-body electromyostimulation (WB-EMS)

Keywords

Whole-body electromyostimulation (WB-EMS), Postmenopausal women, Cardiometabolic health, Quality of life, Electromyostimulation, Obesity, 6-minute walk test

Medical subject headings

Overweight, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Whole-body electromyostimulation (WB-EMS) trainingOther

  Participants will complete a 16-week supervised exercise program consisting of two sessions per week, with at least 48 hours between consecutive sessions. The WB-EMS group will perform 20-minute sessions while receiving bipolar electrical stimulation at 85 Hz with a pulse width of 350 μs, using an intermittent 4-second stimulation/4-second rest pattern. Exercises will include squats, lunges, upper-body pushing and pulling movements, and trunk exercises targeting major muscle groups. Stimulation intensity will be individually adjusted according to participants' tolerance, with a target perceived intensity of approximately 5-7 on a 0-10 scale.

• Supervised exercise without whole-body electromyostimulation (WB-EMS)Behavioural

  The control group will perform the same exercise program without electrical stimulation. Exercise type, session duration, weekly frequency, intervention duration, supervision, and progression will be matched between groups to isolate the additional effect of WB-EMS.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Body Mass Index (BMI)

   BMI calculated as weight (kg) divided by height squared (m²)

   Measured: Baseline and after the 16 weeks of the training intervention.

2. Body fat percentage

   Bodyfat percentage determined from four skinfold sites (biceps, triceps, subscapular, and supra-iliac) using a calibrated Harpenden Skinfold Caliper. Measurements expressed as %.

   Measured: Baseline and after the 16 weeks of the training intervention

3. Waist circumference

   Measured at the narrowest point between the rib cage and iliac crest using a non-elastic tape measure. Measurements expressed in cm.

   Measured: Baseline and after the 16 weeks of the training intervention.]

4. Hip circumference

   Measured at the widest point of the hips using a non-elastic tape measure. Measurements expressed in cm.

   Measured: Baseline and after the 16 weeks of the training intervention

5. Total Cholesterol

   Plasma total cholesterol concentration (mg/dL).

   Measured: Baseline and after the 16 weeks of the training intervention.

6. Triglycerides

   Plasma triglyceride concentration (mg/dL)

   Measured: Baseline and after the 16 weeks of the training intervention

7. High-Density Lipoprotein (HDL) Cholesterol

   Plasma HDL cholesterol concentration (mg/dL)

   Measured: Baseline and after the 16 weeks of the training intervention

8. Low-Density Lipoprotein (LDL) Cholesterol

   Plasma LDL cholesterol concentration (mg/dL)

   Measured: Baseline and after the 16 weeks of the training intervention.

9. 6-Minute Walk Test (6MWT) Distance

   Distance walked in 6 minutes on a 30-meter straight corridor

   Measured: Baseline and after the 16 weeks of the training intervention.

10. Menopause-specific quality-of-life score (MENQOL)

    Menopause-specific quality of life will be assessed using the validated Arabic version of the 29-item Menopause-Specific Quality of Life Questionnaire (MENQOL). Higher scores indicate poorer quality of life.

    Measured: Baseline and after the 16 weeks of the training intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted17 Sep 2026
2. Study start20 Sep 2026 (estimated)
3. Primary completion27 Jan 2027 (estimated)
4. Study completion27 Jan 2027 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Postmenopausal WomenStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.